Back to Search
Start Over
Comparison of prostate cancer detection rates between magnetic resonance imaging-targeted biopsy and transrectal ultrasound-guided biopsy according to Prostate Imaging Reporting and Data System in patients with PSA ≥4 ng/mL: a systematic review and meta-analysis
- Source :
- Translational andrology and urology. 8(6)
- Publication Year :
- 2020
-
Abstract
- BACKGROUND: Previous studies have investigated magnetic resonance imaging-targeted biopsy (MRI-TBx) on the detection for prostate cancer (PCa). Prostate Imaging Reporting and Data System (PI-RADS), as a standardized MRI reporting system, has widely been used in the management of PCa. However, basing the PI-RADS score, the comparability between MRI-TBx and transrectal ultrasound-guided biopsy (TRUS-Bx) in diagnosing PCa remained inconsistent or even controversial. Thus, this systematic meta-analysis aimed to assess the value of PI-RADS in sifting better prostate biopsy method. METHODS: A meta-analysis including 10 articles was performed. In these included studies, biopsy-naive subjects with concerning PSA levels and/or an abnormal digital rectal examination (DRE) were consecutively enrolled by referral from urologists. All subjects underwent multiparameter MRI (mpMRI) prostate and the results were scored independently by PI-RADS. Subjects with equivocal (PI-RADS 3) and intermediate/high-risk (PI-RADS 4/5) lesions underwent MRI-TBx and followed by TRUS-Bx performed by a urologist. The online databases PubMed, Embase and Web of Science were searched to find all correlated articles until October 1(st), 2019. Data were pooled by odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of the associations. Subgroup analyses were conducted based on Gleason score. RESULTS: Overall, 10 studies were included in this meta-analysis from January, 2015 to June, 2019. In the comparison of the detection of MRI-TBx and TRUS-Bx in PCa patients, TRUS-Bx had a significant advantage in overall PCa detection compared with MRI-TBx (OR =0.78, 95% CI: 0.62–0.98) in PI-RADS 3. Basing subgroup analysis of Gleason score (csPCa: Gleason score ≥7; non-csPCa: Gleason score
- Subjects :
- medicine.medical_specialty
Prostate biopsy
medicine.diagnostic_test
business.industry
Urology
030232 urology & nephrology
Magnetic resonance imaging
Subgroup analysis
Rectal examination
medicine.disease
urologic and male genital diseases
03 medical and health sciences
Prostate cancer
0302 clinical medicine
medicine.anatomical_structure
Reproductive Medicine
Prostate
030220 oncology & carcinogenesis
Meta-analysis
Biopsy
medicine
Original Article
Radiology
business
Subjects
Details
- ISSN :
- 22234691
- Volume :
- 8
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- Translational andrology and urology
- Accession number :
- edsair.doi.dedup.....df25cf1c67bebe688fe779d45448cc04